Ankit Mahadevia's most recent trade in Spero Therapeutics Inc was a trade of 20,000 Common Stock done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Spero Therapeutics Inc | Ankit Mahadevia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 20,000 | 709,866 (3%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 05 Feb 2025 | 55,260 | 689,866 (3%) | 0% | 0.8 | 43,103 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 05 Feb 2025 | 13,959 | 745,126 (3%) | 0% | 0.8 | 10,888 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director | Sale of securities on an exchange or to another person at price $ 1.35 per share. | 27 Aug 2024 | 5,912 | 759,085 (3%) | 0% | 1.3 | 7,981 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 764,997 (3%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director | Sale of securities on an exchange or to another person at price $ 1.37 per share. | 02 Feb 2024 | 63,795 | 744,997 (3%) | 0% | 1.4 | 87,399 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 28 Aug 2023 | 9,040 | 788,792 (4%) | 0% | 1.3 | 11,390 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.81 per share. | 03 Feb 2023 | 12,286 | 797,832 (4%) | 0% | 1.8 | 22,238 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 531,914 | 810,118 (4%) | 2% | 0 | Common Stock | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 187,730 | 187,730 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 134,168 | 278,204 (1%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2021 | 8,000 | 486,809 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.58 per share. | 27 Dec 2021 | 8,000 | 144,036 (0%) | 0% | 14.6 | 116,666 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 27 Dec 2021 | 8,000 | 152,036 (0%) | 0% | 5.9 | 47,200 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2021 | 78,219 | 144,036 (0%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 179,319 | 179,319 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2020 | 7,370 | 494,809 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.43 per share. | 03 Nov 2020 | 7,370 | 65,817 (0%) | 0% | 14.4 | 106,335 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 03 Nov 2020 | 7,370 | 73,187 (0%) | 0% | 5.9 | 43,483 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2020 | 2,137 | 502,179 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.27 per share. | 03 Nov 2020 | 2,137 | 65,817 (0%) | 0% | 14.3 | 30,490 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 03 Nov 2020 | 2,137 | 67,954 (0%) | 0% | 5.9 | 12,608 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Oct 2020 | 20 | 504,316 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.25 per share. | 23 Oct 2020 | 20 | 65,817 (0%) | 0% | 14.3 | 285 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 23 Oct 2020 | 20 | 65,837 (0%) | 0% | 5.9 | 118 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.28 per share. | 13 Oct 2020 | 14,367 | 65,817 (0%) | 0% | 14.3 | 205,212 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 13 Oct 2020 | 14,367 | 80,184 (0%) | 0% | 5.9 | 84,765 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2020 | 14,367 | 504,441 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2020 | 105 | 504,336 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 13 Oct 2020 | 105 | 65,922 (0%) | 0% | 5.9 | 620 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.25 per share. | 13 Oct 2020 | 105 | 65,817 (0%) | 0% | 14.2 | 1,496 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 08 Sep 2020 | 774 | 66,591 (0%) | 0% | 5.9 | 4,567 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.25 per share. | 08 Sep 2020 | 774 | 65,817 (0%) | 0% | 14.3 | 11,030 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2020 | 774 | 518,808 | - | - | Stock Option (Right to Buy) |